CL2015001246A1 - Derivados de bendamustina y los metodos de su uso - Google Patents

Derivados de bendamustina y los metodos de su uso

Info

Publication number
CL2015001246A1
CL2015001246A1 CL2015001246A CL2015001246A CL2015001246A1 CL 2015001246 A1 CL2015001246 A1 CL 2015001246A1 CL 2015001246 A CL2015001246 A CL 2015001246A CL 2015001246 A CL2015001246 A CL 2015001246A CL 2015001246 A1 CL2015001246 A1 CL 2015001246A1
Authority
CL
Chile
Prior art keywords
methods
bendamustine
bendamustine derivatives
derivatives
bendamustina
Prior art date
Application number
CL2015001246A
Other languages
English (en)
Spanish (es)
Inventor
Roger P Bakale
Peter D Brown
Jian Chen
Anthony S Drager
Rachel Y Labell
Robert E Mckean
Piyush R Patel
Renee C Roemmele
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of CL2015001246A1 publication Critical patent/CL2015001246A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CL2015001246A 2012-11-12 2015-05-08 Derivados de bendamustina y los metodos de su uso CL2015001246A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12
PCT/US2013/069550 WO2014075035A1 (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Publications (1)

Publication Number Publication Date
CL2015001246A1 true CL2015001246A1 (es) 2016-01-15

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001246A CL2015001246A1 (es) 2012-11-12 2015-05-08 Derivados de bendamustina y los metodos de su uso

Country Status (17)

Country Link
US (7) US9452988B2 (enExample)
EP (1) EP2917183A1 (enExample)
JP (1) JP6262246B2 (enExample)
KR (1) KR20150086308A (enExample)
AR (1) AR093457A1 (enExample)
AU (1) AU2013342015B2 (enExample)
BR (1) BR112015010501A2 (enExample)
CA (1) CA2890462A1 (enExample)
CL (1) CL2015001246A1 (enExample)
EA (1) EA029706B1 (enExample)
HK (2) HK1212977A1 (enExample)
IL (1) IL238662A (enExample)
MX (1) MX2015005805A (enExample)
PH (1) PH12015501024A1 (enExample)
SG (1) SG11201503560TA (enExample)
TW (1) TWI598341B (enExample)
WO (1) WO2014075035A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2918588T3 (en) 2010-05-20 2017-08-28 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
MX2015005805A (es) 2012-11-12 2016-04-15 Ignyta Inc Derivados de bendamustina y métodos para utilizarlos.
MX362032B (es) 2013-03-12 2019-01-04 Cephalon Inc Formulaciones nanoparticuladas y macroparticuladas.
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
WO2018013783A1 (en) * 2016-07-13 2018-01-18 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU2002239405A1 (en) 2000-12-01 2002-06-11 Enzon, Inc. Tetrapartate prodrugs
WO2003086369A2 (en) * 2002-04-05 2003-10-23 Valorisation-Recherche, Societe En Commandite Stealthy polymeric biodegradable nanospheres and uses thereof
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP5670335B2 (ja) 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
EP2349219A4 (en) * 2008-09-29 2013-05-01 Univ Mercer BIOLOGICALLY EFFECTIVE SUBSTANCES CAPSULATING NANO BEADS AND METHOD FOR FORMULATING NANO BEADS
CN102177140B (zh) 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法
HRP20140204T1 (hr) 2008-12-03 2014-04-11 Astellas Deutschland Gmbh Oralni oblici doziranja bendamustina
DK2575784T3 (en) 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
TWI455722B (zh) 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
WO2012059935A1 (en) 2010-11-01 2012-05-10 Shilpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
DE102010055499A1 (de) 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
WO2012158776A2 (en) 2011-05-17 2012-11-22 University Of South Alabama Combination therapy for treatment of cancer
WO2013046223A1 (en) 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
SI2656843T1 (sl) 2012-04-26 2015-06-30 Helmut Schickaneder Estri bendamustina in povezane spojine ter njihova medicinska uporaba
CA2875455C (en) 2012-06-19 2020-03-10 Helmut Schickaneder Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
EP2882459A1 (en) 2012-08-10 2015-06-17 University of North Texas Health Science Center Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
MX2015005805A (es) * 2012-11-12 2016-04-15 Ignyta Inc Derivados de bendamustina y métodos para utilizarlos.

Also Published As

Publication number Publication date
IL238662A (en) 2017-08-31
US20170182008A1 (en) 2017-06-29
IL238662A0 (en) 2015-06-30
EA029706B1 (ru) 2018-05-31
JP6262246B2 (ja) 2018-01-17
US9913827B2 (en) 2018-03-13
TW201439069A (zh) 2014-10-16
US20160016912A1 (en) 2016-01-21
AR093457A1 (es) 2015-06-10
US20160289198A1 (en) 2016-10-06
US20180147186A1 (en) 2018-05-31
AU2013342015B2 (en) 2016-11-24
TWI598341B (zh) 2017-09-11
BR112015010501A2 (pt) 2017-07-11
CN105051016A (zh) 2015-11-11
CA2890462A1 (en) 2014-05-15
HK1215701A1 (zh) 2016-09-09
PH12015501024A1 (en) 2015-07-27
US9452988B2 (en) 2016-09-27
AU2013342015A1 (en) 2015-05-28
US9630926B2 (en) 2017-04-25
EA201590925A1 (ru) 2015-09-30
MX2015005805A (es) 2016-04-15
EP2917183A1 (en) 2015-09-16
SG11201503560TA (en) 2015-06-29
US9150517B2 (en) 2015-10-06
KR20150086308A (ko) 2015-07-27
HK1212977A1 (zh) 2016-06-24
JP2015536996A (ja) 2015-12-24
WO2014075035A1 (en) 2014-05-15
US20150274675A1 (en) 2015-10-01
US20150232427A1 (en) 2015-08-20
US20150246023A1 (en) 2015-09-03
US9149464B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CR20150316A (es) Compuestos y sus métodos de empleo
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
UY35500A (es) Indazoles sustituidos con heteroarilo
UY36311A (es) Indazoles sustituidos con bencilo
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY36076A (es) Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
AR091837A1 (es) Compuestos para inmunoterapia dirigida
MX2015010312A (es) Metodos para tratamiento del melanoma.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.